BioCorRx (BICX) Accounts Payables (2010 - 2026)

BioCorRx has disclosed Accounts Payables across 17 years of filings, most recently posting $6.6 million for Q1 2026.

• Accounts Payables for Q1 2026 came in at $6.6 million, down 39.38% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.6 million (down 39.38% YoY), and the FY2025 annual result was $6.4 million, up 14.13% from the prior year.
• Accounts Payables came in at $6.6 million for Q1 2026 at BioCorRx, up from $6.4 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $11.8 million in Q2 2025 to a low of $2828.0 in Q3 2025.
• The 5-year median for Accounts Payables is $4.6 million (2023), against an average of $5.2 million.
• Peak annual rise in Accounts Payables reached 121.49% in 2025, while the deepest fall reached 99.95% in 2025.
• BioCorRx's Accounts Payables stood at $3.9 million in 2022, then rose by 18.97% to $4.6 million in 2023, then climbed by 19.91% to $5.6 million in 2024, then climbed by 14.13% to $6.4 million in 2025, then advanced by 3.49% to $6.6 million in 2026.
• The last three Accounts Payables figures came in at $6.6 million (Q1 2026), $6.4 million (Q4 2025), and $2828.0 (Q3 2025), per Business Quant data.